Axplora has announced plans to build a 4,500sqm R&D and laboratory hub at its Farmabios site in Gropello […]
Category: News
Ondine Biomedical has announced the North American phase 3 study has reached more than 93% enrolment, bringing the […]
Early trial shows more than 50% LRRK2 reduction and supports expansion into other neurodegenerative conditions
Lead Alzheimer’s candidate shows clear biological effects and antidepressant potential
Deal covers up to five candidates including SB36 as company expands global pipeline
Study to explore mechanism behind novel oral therapy for muscle‑sparing weight loss
Financing and global licensing deal to accelerate phase 2b development of AP306
Collaboration aims to streamline and scale next‑generation Treg therapy production
Study to assess oral therapy for patients with inadequate response to TNF inhibitors
